| Today’s Big NewsSep 11, 2024 |
| By Fraiser Kansteiner Lilly revealed that its weekly insulin candidate efsitora alfa met its primary endpoints for reducing the A1C measure of blood sugar across two more trials in the company's five-study phase 3 development program. |
|
|
|
By Conor Hale The agency's researchers will conduct experiments to measure the amounts of metals that may leech out of tampons and enter the body under everyday use. |
By Kevin Dunleavy Just two years into its existence, radioisotope producer PanTera has drawn 93 million euros ($102.5 million) in an oversubscribed Series A investment round, led by EQT Life Sciences. It is the largest Series A round ever for a Belgian company in the life sciences sector, according to EQT. |
By Kevin Dunleavy Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria, Sanofi and Regeneron have presented data from a phase 3 trial that could help push the megablockbuster across the finish line in the indication. |
|
Still Time to Shine! Submission deadline for the Fierce Life Sciences Innovation Awards have been extended to September 12. Click to submit your entry and learn more about what winner's will receive.
|
|
By Nick Paul Taylor BridgeBio Pharma is slashing its gene therapy budget and pulling back from the modality after seeing the results of a phase 1/2 clinical trial. CEO Neil Kumar, Ph.D., said the data “are not yet transformational,” driving BridgeBio to shift its focus to other drug candidates and ways to treat disease. |
By Conor Hale The Massachusetts-based company combines optical coherence tomography and near-infrared spectroscopy—two light-based methods for determining the properties of tissue. |
By Darren Incorvaia Hundreds of millions of people who live in, or are descended from, regions where the malaria-causing protozoan Plasmodium vivax is prevalent have inherited a unique blood type that evolved to prevent malaria infection. People with the Duffy null phenotype—who are primarily of African and Middle Eastern descent—have red blood cells that lack a surface protein called the Duffy antigen, which is what P. vivax uses to infect cells. |
By Zoey Becker It was a busy day for Sanofi and Regeneron as the Dupixent partners look to expand the reach of Dupixent into several new diseases. |
By James Waldron GSK’s attempt to develop the first vaccine for herpes simplex virus has ended in failure, leaving the race open for the likes of Moderna and BioNTech. |
By Conor Hale Withings describes it as the first FDA-cleared device that can help diagnose obstructive sleep apnea without any wearable sensors, wires, masks or straps. |
By James Waldron Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage trials, the pharma’s head of metabolism R&D has told Fierce Biotech. |
Fierce podcastsDon’t miss an episode |
| In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. |
|
|---|
|
|
|
Bringing new oncology therapies to market is challenging, but novel, safer treatments are needed. Download the new QPS Oncology white paper to learn more about oncology clinical trials, challenges and solutions.
|
|
| WhitepaperFacing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
| WhitepaperWe interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
